Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
40 hedge funds and large institutions have $121M invested in Adaptimmune Therapeutics in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 11 closing their positions.
7.02% more ownership
Funds ownership: 0% → 7.02% (+7%)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
13% less funds holding
Funds holding: 46 → 40 (-6)
45% less capital invested
Capital invested by funds: $219M → $121M (-$98.5M)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$579K |
| 2 |
Renaissance Technologies
New York
|
+$558K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$495K |
| 4 |
AG
Artal Group
Luxembourg
|
+$480K |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
+$326K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$3.15M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.99M |
| 3 |
IHM
Iguana Healthcare Management
New York
|
-$959K |
| 4 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
-$622K |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$578K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Group One Trading
Chicago,
Illinois
| – | -$18K | -2,500 | Closed |
|
ADAP Hedge Fund Activity: Q4 2016 in Review
40 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2016, worth a combined $121M — down 45% from $219M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ADAP and 6 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 10 added.
The largest buyer was Vident Investment Advisory, adding an estimated $579K. The largest seller was Putnam Investments, exiting entirely with an estimated $3.15M sold.
- 40 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2016, down from 46 in Q3 2016.
- Funds reported $121M of Adaptimmune Therapeutics stock for Q4 2016, down 45% quarter-over-quarter.
- 6 funds opened new Adaptimmune Therapeutics positions in Q4 2016 and 11 closed out, a net change of -5 holders.
- The largest Adaptimmune Therapeutics buyer in Q4 2016 was Vident Investment Advisory, an estimated $579K added.
- The largest Adaptimmune Therapeutics seller in Q4 2016 was Putnam Investments, an estimated $3.15M sold.
Based on aggregated 13F filings for Q4 2016.